Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The current endothelin receptor classification: time for reconsideration?

W A Bax1, P R Saxena

  • 1Department of Pharmacology, Cardiovascular Research Institute COEUR, Faculty of Medicine and Health Sciences, Eramus University Rotterdam, The Netherlands.

Trends in Pharmacological Sciences
|October 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk.

Clinical therapeutics·2023
Same author

Lifestyle management to prevent atherosclerotic cardiovascular disease: evidence and challenges.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2021
Same author

An appeal to our government for nationwide policies in the prevention of cardiovascular disease.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2021
Same author

Screening for renal involvement in ANCA-associated vasculitis: room for improvement?

The Netherlands journal of medicine·2017
Same author

A 73-year-old male with jaundice and acute kidney injury. Bile cast nephropathy.

The Netherlands journal of medicine·2014
Same author

5-HT1 receptors in migraine pathophysiology and treatment.

European journal of neurology·2013
Same journal

Targeting developmental reprogramming: hPSC insights for cancer interception.

Trends in pharmacological sciences·2026
Same journal

July 2026 issue first authors.

Trends in pharmacological sciences·2026
Same journal

Chronobiomaterials for circadian-aligned brain therapeutics.

Trends in pharmacological sciences·2026
Same journal

Biosensors for translatable GPCR bias.

Trends in pharmacological sciences·2026
Same journal

ECM stiffness and epigenetics in organ fibrosis.

Trends in pharmacological sciences·2026
Same journal

Which HTT transcript to lower?

Trends in pharmacological sciences·2026
See all related articles

Researchers are exploring endothelins and their receptors (ETA and ETB) for new disease treatments. Some observed effects suggest the existence of atypical endothelin receptors beyond the known ETA and ETB types.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Drug Discovery

Background:

  • Endothelins are implicated in various diseases, making them targets for novel therapeutic strategies.
  • Significant advancements in endothelin research have led to the identification and characterization of ETA and ETB receptors.
  • Selective compounds targeting ETA and ETB receptors have been developed.

Purpose of the Study:

  • To provide a comprehensive overview of endothelin receptors.
  • To specifically address the existence and characteristics of atypical endothelin receptors.
  • To discuss the implications of these findings for pharmacological research and therapeutic development.

Main Methods:

  • Review of existing literature on endothelin receptor characterization.

Related Experiment Videos

  • Analysis of pharmacological data from various assays.
  • Discussion of molecular and functional properties of identified receptors.

    • Main Results:

    • Established ETA and ETB receptors are well-characterized.
    • Assay data indicates that certain biological effects are mediated by receptors not conforming to current ETA or ETB criteria.
    • Evidence suggests the presence of atypical endothelin receptors.

    Conclusions:

    • The current understanding of endothelin receptor subtypes may be incomplete.
    • Atypical endothelin receptors warrant further investigation for their role in disease.
    • Further research into atypical receptors could unveil new therapeutic targets and approaches.